FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Instruc	tion 1(b).			Filed	oursuan or Sec	t to Section tion 30(h)	n 16(a of the	a) of the Secu Investment C	rities Excha Company Ac	nge Act of 1 t of 1940	.934		Tiours per	response.	0.5
	1. Name and Address of Reporting Person* Whitfield Dianne C.				2. Issuer Name and Ticker or Trading Symbol Tarsus Pharmaceuticals, Inc. [TARS]						eck all appli Directo	tor 10%		Owner	
	RSUS PHAI	irst) RMACEUTICA ANYON ROAD			3. Date of Earliest Transaction (Month/Day/Year) 03/09/2022						A below) Chief	below) below Chief Human Resources Of		icer	
(Street) IRVINE (City)	C.		92618 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
	`		le I - Non-D	erivat	ive S	ecuritie	s Ac	auired. D	isposed	of. or Be	neficial	lv Owned	<u> </u>		
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			Transac	ction 2A. Deemed Execution Date,		3. Transacti Code (Ins	4. Secur	rities Acquir ed Of (D) (Ins	ed (A) or	5. Amou Securitie Benefici Owned F	nt of 6. es Fe ally (E	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect		
						Code V	Amount	(A) o	r Price	Reported Transact (Instr. 3	tion(s)				
		-	Fable II - De (e.					uired, Dis s, options				Owned		·	
1. Title of Derivative Security (Instr. 3)	Conversion or Exercise (Month/Day/Year) Execution if any		3A. Deemed Execution Date if any (Month/Day/Yea	Cod	nsaction de (Instr			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)
				Cod	de V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$19.59	03/09/2022		A		60,846		(1)	03/08/2032	Common Stock	60,846	\$0	60,846	D	
Restricted Stock Units	(2)	03/09/2022		A		17,850		(3)	(3)	Common Stock	17,850	\$0	17,850	D	
Restricted Stock	(2)	03/09/2022		A		34,171		(4)	(4)	Common Stock	34,171	\$0	34,171	D	

Explanation of Responses:

- 1. 25% of the option shares shall vest on March 9, 2023, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service.
- 2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
- 3. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.
- 4. 30% of the RSUs will vest on November 29, 2022 and 70% of the RSUs will vest on November 29, 2023, subject to the Reporting Person's continuous service.

Remarks:

/s/ Leonard M. Greenstein, Attorney-in-Fact

03/11/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.